Current Report Filing (8-k)
September 24 2019 - 6:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
|
Date
of Report (Date of Earliest Event Reported):
|
September
23, 2019
|
|
|
PROTAGENIC
THERAPEUTICS, INC.
|
|
(Exact
name of Company as specified in its charter)
|
|
Delaware
|
|
000-51353
|
|
06-1390025
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
|
149
Fifth Avenue, Suite 500, New York, NY
|
|
10010
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
212-994-8200
(Company’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Ticker
symbol(s)
|
|
Name
of each exchange on which registered
|
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Exchange Act of 1934.
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.07. Submission of Matters to a Vote of Security Holders.
Protagenic
Therapeutics, Inc. (the “Company”) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”)
on September 23, 2019. Holders of an aggregate of 10,261,419 shares of the Company’s Common Stock at the close of business
on July 30, 2019 were entitled to vote at the Annual Meeting, of which 5,544,957 shares were present in person or represented
by proxy. At the Annual Meeting, the Company’s stockholders voted as follows:
Proposal
One: The stockholders elected each of the following individuals as a director for a one year term expiring on the date
of the Company’s 2020 Annual Meeting of Stockholders and until their successors have been duly elected and qualified.
|
Name
|
|
For
|
|
|
Against
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
|
Garo H. Armen
|
|
|
5,433,802
|
|
|
|
0
|
|
|
|
109
|
|
|
|
-
|
|
|
Robert B. Stein
|
|
|
5,433,801
|
|
|
|
0
|
|
|
|
110
|
|
|
|
-
|
|
|
Khalil Barrage
|
|
|
5,433,011
|
|
|
|
0
|
|
|
|
900
|
|
|
|
-
|
|
|
Brian J. Corvese
|
|
|
5,433,812
|
|
|
|
0
|
|
|
|
99
|
|
|
|
-
|
|
|
Josh Silverman
|
|
|
5,433,013
|
|
|
|
0
|
|
|
|
898
|
|
|
|
-
|
|
Proposal
Two: The stockholders ratified the selection of MaloneBailey LLP as the Company’s independent registered public
accounting firm for the fiscal year ending December 31, 2019.
|
For
|
|
Against
|
|
Abstain
|
|
5,544,387
|
|
556
|
|
14
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
PROTAGENIC
THERAPEUTICS, INC.
|
|
|
|
|
|
Date:
September 24, 2019
|
By:
|
/s/
Alexander K. Arrow
|
|
|
Name:
|
Alexander
K. Arrow
|
|
|
Title:
|
Chief
Financial Officer
|